Compare Gogoro Inc (GGR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Gogoro Inc trades at $2.99 (market cap $65.24M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 15× Gogoro Inc's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GGR | MRVI | |
|---|---|---|
Market Cap | $65.24M | $977.37M |
Volume | 11,432 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $4.66 | $9.00 |
52-Week Low | $2.20 | $2.83 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $351.68M | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $3.24, up 2.53% with a bullish technical signal despite negative profitability metrics. The company reported $281.48M revenue for 2025 but a net loss of $79.97M, though losses are projected to narrow in 2026. Recent developments include $61.8M in new equity investments and board appointments to strengthen governance. Technical indicators show bullish momentum with support at $3.00.
While technical momentum appears positive, fundamental challenges persist with negative margins and cash flow. The investment case hinges on Gogoro's ability to achieve profitability amid expansion costs. Analyst consensus remains cautious with 100% hold ratings, suggesting investors await clearer profitability signals before committing.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
